DIABETES: SGLT2 inhibitors and diabetic ketoacidosis — a growing concern


    loading  Checking for direct PDF access through Ovid

Abstract

Diabetic ketoacidosis is a worrying complication associated with the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes mellitus (T1DM) or T2DM. A recent analysis of data in the FDA Adverse Event Reporting System by Fadini and colleagues adds to this concern.Refers to Fadini, G. P. et al. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologiahttp://dx.doi.org/10.1007/s00125-017-4301-8 (2017)

    loading  Loading Related Articles